1. Medtech Insight
  2. >>Archive

CorMatrix CE marks CorMatrix biomaterial

 
• By Joseph Harvey

CorMatrix Cardiovascular has CE marked its extracellular matrix (ECM) biomaterial for sale in Europe. The CorMatrix ECM is used to repair heart structures during open heart surgery. The biomaterial is sutured onto the heart tissue and serves as a scaffold; over time, cells can infiltrate and replace the ECM with native tissue. According to Atlanta, Georgia-based CorMatrix, the ECM works differently to similar materials as it allows for the repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can lead to unwanted effects. The technology has been commercially available in the US since 2006 and has been used in approximately 20,000 cardiac surgery procedures.

CorMatrix Cardiovascular has CE marked its extracellular matrix (ECM) biomaterial for sale in Europe. The CorMatrix ECM is used to repair heart structures during open heart surgery. The biomaterial is sutured onto the heart tissue and serves as a scaffold; over time, cells can infiltrate and replace the ECM with native tissue. According to Atlanta, Georgia-based CorMatrix, the ECM works differently to similar materials as it allows for the repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can lead to unwanted effects. The technology has been commercially available in the US since 2006 and has been used in approximately 20,000 cardiac surgery procedures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: July 14–18, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 
• By Amanda Maxwell

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 
• By Natasha Barrow

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.